1nhaler

Overview

Based in Scotland, 1nhaler is a drug delivery device developer creating a single-dose, propellant-free dry powder inhaler [1]. The company’s primary innovation is a portable, low-cost device manufactured primarily from FSC-certified cardboard that transforms from a flat, credit-card shape into a functional three-dimensional inhaler [0, 1]. Designed to be a sustainable alternative to conventional plastic capsule inhalers, the 1nhaler device weighs approximately two grams [0]. While its lead project focuses on salbutamol for asthma relief to establish technical proof of concept, the company aims to support a broad range of inhalable treatments, including vaccines and medications for conditions such as epilepsy, allergies, and Parkinson’s disease [0, 1]. The firm has raised $2,952,180 in total funding. According to the company, it has successfully completed its drug-device combination freeze and is currently preparing for GMP-compliant manufacturing to support human clinical trials scheduled for early 2027 [1]. The team is composed of industry veterans with significant experience from large pharmaceutical companies including GSK, Novartis, and AstraZeneca [0, 1].

Funding

Total disclosed: $3M across 1 round. Computed only from sourced rounds.

1nhaler funding rounds

Date	Company	Amount	Stage	Lead	Other investors	Sector	Sources
Nov 3	1nhaler	£2.2M	—	Archangels	Scottish Enterprise +1	Hardware & Semiconductors	1

• Nov 3

  1nhaler£2.2M

  Led by Archangels · with Scottish Enterprise, +1

  Hardware & Semiconductors1 source

Investors

• Archangels
• Scottish Enterprise
• BBB Investments